Leigh L. Speicher

Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19

Raymund R. Razonable, Colin Pawlowski, John C. O’Horo et al. · EClinicalMedicine · 2021 · 134 citations · Full text

Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019

Ravindra Ganesh, Lindsey M. Philpot, Dennis M. Bierle et al. · The Journal of Infectious Diseases · 2021 · 102 citations · Full text

Implementation of a multisite, interdisciplinary remote patient monitoring program for ambulatory management of patients with COVID-19

Jordan Coffey, Laura A. Christopherson, Amy E. Glasgow et al. · npj Digital Medicine · 2021 · 64 citations · Full text

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19

Raymund R. Razonable, Nicole C.E. Aloia, Ryan J. Anderson et al. · Mayo Clinic Proceedings · 2021 · 54 citations · Full text

Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

Ravindra Ganesh, Colin Pawlowski, John C. O’Horo et al. · Journal of Clinical Investigation · 2021 · 46 citations · Full text